Access to Medicine for Low- and Middle-Income Countries: Meeting Needs in Underserved and Unserved Countries
Low- and middle-income countries (LMICs), defined by the World Bank as having a gross national income (GNI) of below $13,995, are home to nearly 80% of the global population.
September 8, 2025
by Suzanne Elvidge
Meeting global quality standards: A look at CNS & cardiovascular APIs
Active pharmaceutical ingredients (APIs) are the active ingredients used in pharmaceutical manufacturing and are formulated with excipients to create the finished drug form.
August 22, 2025
by Suzanne Elvidge
Radioconjugate Therapy: The Approval Process And the Market Landscape
Radioconjugates combine targeted ligands with radioisotopes, enabling precision cancer therapy and theranostics. The $7.5B market by 2033 demands strict FDA safety/CMC data for NDA/BLA approval.
August 22, 2025
by Suzanne Elvidge
Drug-Device Combination Products: Making a Step Towards Better Adherence
More than half of the world’s population takes at least one medication daily, but the safety and efficacy data from clinical trials isn’t always fully reflected in real world use.
August 1, 2025
by Suzanne Elvidge
Direct-to-Consumer and Direct-to-Patient Healthcare Models
Accessing healthcare can be complex, and this complexity is driven by a number of different factors.
July 24, 2025
by Suzanne Elvidge
Niche API Opportunities: Chloramphenicol and Immune Regulators
The global active pharmaceutical ingredients (API) market is consistently growing, in line with the increases in size of the pharmaceutical industry.
July 18, 2025
by Suzanne Elvidge
Beyond Antibiotics: The Expanding Role of Anti-Infective APIs in Bacterial Infection
Beyond antibiotics, novel anti-infective approaches include AMPs targeting biofilms, FMT capsules ,nanoparticle delivery systems, and synbiotics to combat the global AMR crisis.
June 13, 2025
by Suzanne Elvidge
Radioconjugates: Targeting for Precision
The development of radioconjugates – targeted molecules designed to carry radionuclides directly to cancerous cells, lowering systemic exposure and increasing the precision of treatment.
May 6, 2025
by Suzanne Elvidge
Now and Next in Type 2 Diabetes
Type 2 diabetes, the most common form of diabetes, affects more than 800 million adults worldwide.
May 6, 2025
by Suzanne Elvidge
Oncolytic viruses in cancer treatment
Naturally occurring oncolytic viruses, which replicate in tumour cells and trigger apoptosis and immune responses while sparing healthy cells, were first discovered at the turn of the 19th century.
April 21, 2025
by Suzanne Elvidge
Molecular Editing in Drug Discovery: Making Peripheral and Skeletal Changes
Drug discovery often begins with high-throughput screening of large libraries to identify potential hits.
April 1, 2025
by Suzanne Elvidge
Falling off the Patent Cliff: Patent Expirations in 2025 and Onwards
In the early 2010s, a new phenomenon hit the pharmaceutical industry – the patent cliff.
March 31, 2025
by Suzanne Elvidge